Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of February 2026. The report serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them, rather than a periodic financial report.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics for the company. The only financial data disclosed relates to a specific executive compensation event:
- Transaction Type: Cash payment following the vesting of notional Ordinary Shares under the Deferred Investment Award Programme.
- Instrument: Ordinary shares of 31 1/2 pence each (ISIN: GB00BN7SWP63).
- Volume: 8,996.851 notional Ordinary Shares.
- Price: £22.68 per share.
- Gross Value: £204,048.58 (subject to applicable tax withholding).
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses the vesting of 25% of an award made on February 18, 2021, to Tony Wood, Chief Scientific Officer, on February 18, 2026.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of a specific transaction required under the Securities Exchange Act of 1934.
Key Facts for Investor Verification
- Verify the identity of the recipient: Tony Wood, Chief Scientific Officer.
- Confirm the transaction date: February 18, 2026.
- Note that the payment is a cash settlement for notional shares, not a direct stock issuance.
- Understand that this filing does not reflect the company's overall financial performance for the period.